Therapeutic Areas
Therapeutic Areas
Pharmaceutical Clinical
Trials & Pipeline
Alcon is the global leader in eye care, dedicated to helping people see brilliantly for over 75 years. We're excited about what’s next.
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of Acoltremon (AR-15512), a Novel Topical Drug Candidate for Dry Eye
Acoltremon, a topical transient receptor potential melastatin 8 (TRPM8) agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease. In both pivotal efficacy and safety studies (COMET-2 and COMET-3), the primary endpoint was achieved (P<0.0001).
Acoltremon is an investigational drug product that has not been submitted to the U.S. Food and Drug Administration (FDA) for approval and is not currently commercially available.
Recent Scientific Publications
GLAUCOMA
The Rationale for Applying a Visual Field Rate of Progression Analysis Using a Hierarchical, Censored, Bayesian Model to the 5-Yeah HORIZON Data
GLAUCOMA
The HYDRUS Microstent - Mechanisms of Action and Clinical Efficacy
SURGICAL RETINA
A More Effective Approach to Internal Limiting Membrane Peeling
ACOLTREMON TIMELINE
COMET: Clinical Development Program for Acoltremon
PIPELINE FOCUS
We continue to build our pharmaceutical pipeline focusing on promising and large categories.